The human leucocyte antigen (HLA) association with type 1 diabetes (T1D) is well known but there are limited studies investigating the association between β-cell autoantibodies and HLA genes. We evaluated the prevalence of GAD65 and IA-2 autoantibodies (GADA and IA2A) in 252 T1D patients from North India and investigated the genetic association of GADA and IA2A with HLA class I and class II genes/haplotypes. GADA and IA2A were detected in 50.79% and 15.87% of T1D patients, respectively, while only 8.73% had both GADA and IA2A. HLA-DRB103 was observed to be significantly higher in GADA+ T1D patients as compared to GADA– (91.41% vs. 66.13%, Bonferroni- ; ; 95% CI: 2.67-11.08). Similarly, HLA-DQB102 was found to be significantly increased in GADA+ patients (94.53%, ; ; 95% CI: 2.7-14.49) as compared to GADA– (73.39%). The frequencies of HLA-DRB104 and DQB103 were increased in IA2A+ patients (45.0% and 52.5%, respectively) as compared to that in IA2A– (25.94% and 33.96%, respectively). Further, the frequency of DRB103-DQB102 haplotype was found to be significantly increased in GADA+ T1D patients as compared to GADA- (60.55% vs. 41.94%, ; ;
Aim: We planned this study to identify diabetogenic glutamic acid decarboxylase (GAD65) peptides possibly responsible for human leucocyte antigen (HLA)‐DR3/DQ2‐mediated activation of GAD65‐specific CD4 T cells in type 1 diabetes (T1D).Methods: Top 30 GAD65 peptides, found to strongly bind in silico with HLA‐DR3/DQ2 molecules, were selected and grouped into four pools. The peptides were used to stimulate CD4 T cells of study subjects in 16‐h peripheral blood mononuclear cell culture. CD4 T cells' stimulation in terms of interferon‐gamma (IFN‐γ), interleukin (IL)‐17, tumor necrosis factor‐alpha (TNF‐α), and IL‐10 expression was analyzed using flow cytometry.Results: Although all four GAD65 peptide pools (PP1‐4) resulted in significantly higher expression of IFN‐γ by CD4 T cells (p = .003, p < .0001, p = .026, and p = .002, respectively), only pool 2 showed significant increase in IL‐17 expression (p < .0001) in T1D patients vs healthy controls. Interpeptide group comparison for immunogenicity revealed significantly higher IFN‐γ and IL‐17 expressions and significantly lower IL‐10 expression for PP2 compared to other groups (p < .0001, p = .02, and p = .04, respectively) in patients but not in controls. Further, group 2 peptides resulted in significant increase in CD4 T cells' expression of IFN‐γ and IL‐17 (p = .002 for both) and significant decrease in IL‐10 (p = .04) in HLA‐DRB1*03‐DQA1*05‐DQB1*02+ patients vs HLA‐DRB1*03‐DQA1*05‐DQB1*02+ controls. The CD4 T cells' expression of IL‐17 was significantly higher (p = .03) in recently diagnosed vs long‐standing HLA‐DRB1*03‐DQA1*05‐DQB1*02+ T1D patients.Conclusion: GAD65 peptides, particularly those belonging to PP2, induced CD4 T cells to express IFN‐γ and IL‐17 cytokines in T1D patients, suggesting that group 2 peptides possibly presented by HLA‐DR3 molecule to CD4 T cells shift immune balance toward inflammatory phenotype in patients.
18 September 2015 in International Journal of Immunogenetics
The exact cause of psoriasis is still unclear and there is no treatment available for its permanent reemission. The available biologics for disease treatment, are stated to be associated with a high cost of treatment, a significantly increased risk of serious infections, and have also been reported to show major contradictions in patients with tuberculosis and cardiovascular disorders. Therefore, drug repurposing could be an appealing strategy to find novel treatments for psoriasis, saving time, cost and with viable chance of success. The goal of the present study was to identify the FDA approved drugs which can be proposed as potential anti-psoriasis drugs. The known drug target interactions of 19 autoimmune diseases, 4 cardiovascular risk factors, and each of infectious, lung, and mood disorders were retrieved using various public databases, i.e., DrugBank, PharmGKB, clinicaltrial.gov database, TTD, CTD, and the Unified Medical Language System NDF-RT. The drug target interaction of prioritised drugs, obtained using molecular function GO mappings from the QuickGO database through NBI score was analysed using a molecular docking approach. Further, one-SVM algorithm prediction was done to validate the docking outcome and molecular dynamics simulation of top drug-target molecule was performed to propose potential anti-psoriasis drugs. The study identified Pioglitazone, Trimipramine and Dimetindene as top three contender amongst many other drugs as a new indication against psoriasis.